Latest news
AB2 Bio receives USD 30 million from Nippon Shinyaku - Greater Geneva Bern area (GGBa)Greater Geneva Bern area (GGBa) · Mon, 03 Aug 2026 12:07:14 GMTAB2 Bio Receives $30 Million From Nippon Shinyaku For U.S. Tadekinig Alfa Rights, With Up To $600 Million In Milestones And Royalties - Pulse 2.0Pulse 2.0 · Mon, 03 Aug 2026 01:58:58 GMTNS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S. - PR NewswirePR Newswire · Thu, 30 Jul 2026 13:03:00 GMTAB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 06:37:58 GMTQTREX Launches Quantum Interconnect Research Program With Northeastern University and Commercialization Rights to Project IP - MoomooMoomoo · Mon, 27 Jul 2026 11:42:20 GMTQTREX Launches Quantum Interconnect Research Program with Commercialization Rights to Project-Generated IP - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT